Small Bone Innovations Awards Clinipace Four Projects
MORRISVILLE, N.C.-
May 12, 2009-
Clinipace
, a growing digital clinical research organization, announces that Small Bone Innovations (SBi) has awarded four new projects to the company during the first quarter of 2009. These projects primarily include electronic data capture (EDC) and data management services.
SBi offers a broad, clinically proven portfolio of products and technologies to treat trauma and diseases in small bones and joints and has recently acquired the S.T.A.R. total ankle replacement system. “In selecting Clinipace, we found a partner who understands the culture and financial needs of a growing medical device firm. We share a common vision for more project visibility and appreciate their approach to service delivery,” said James O’Connor Vice President, Worldwide Regulatory, Quality and Clinical Affairs, Surgeons Ethics and Compliance at SBi.
“We are investing in multiple clinical projects. This requires a select group of clinical and regulatory service providers to work closely together with SBi. We turned to Clinipace to serve as the glue to hold the projects together from a data management perspective. Having complete real-time visibility into study-level information is critical to our success,” continued O’Connor.
"We’re excited to work with SBi, and we believe our approach to Right-Sized technology-driven service will contribute to the success of these projects,” said Jeff Williams, Chief Executive Officer at Clinipace.
"With a commitment to bringing affordable clinical development services to every life science firm, Clinipace continues to invest in technology and processes that bring much needed transparency to clinical research projects,” continues Williams.
About Small Bone Innovations, Inc.
Small Bone Innovations, Inc. (SBi) was founded in 2004 by Viscogliosi Brothers, LLC, (VB), a New York-based merchant banking firm that specializes in the musculoskeletal/orthopedics sector. VB created SBi as the first company to focus purely on small bones & joints. By integrating established companies and professionals in the field, SBi offers a broad, clinically proven portfolio of products and technologies to treat trauma and diseases in small bones & joints. Today, SBi has more than 130 employees at facilities in New York, NY, Morrisville, PA, Bourg-en-Bresse, France and Donaueschingen, Germany, among other locations worldwide. For more information on SBi, please visit:
www.totalsmallbone.com
About Clinipace
Clinipace is an experienced clinical research solutions company providing on-demand software and clinical services for phase I-IV clinical trials, registries, and investigator-initiated grant management programs. We serve biopharmaceutical and medical device companies as well as academic medical centers. Optimized by TEMPO™, our web-based software platform, we deliver services such as EDC, ePRO, grant management, data management, monitoring, site management, and biostatistics at a 30% – 50% savings compared to similar service providers. Learn more at
http://www.clinipace.com
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
